208511-07-3

Usage

Uses

Used in Pharmaceutical Industry:
3-chloro-4-nitro-1H-indole is used as a chemical intermediate for the synthesis of various pharmaceuticals, leveraging its potential biological and pharmacological activities.
Used in Research Applications:
3-chloro-4-nitro-1H-indole is used as a research compound for studying its potential anticancer, antibacterial, and antifungal properties, contributing to the development of new therapeutic agents.
Used in High-Value Product Production:
3-chloro-4-nitro-1H-indole is used as a key component in the production of high-value products, such as specialty chemicals and materials, due to its unique chemical properties and potential applications.

Upstream product

• 128-09-6 N-chloro-succinimide 
• 4769-97-5 4-nitro-1H-indoIe 

Downstream Products

• 61394-51-2 4-nitro-1,3-dihydroindol-2-one 

Relevant academic research and scientific papers

2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure: wherein: a) R1 is hydrogen; or alkyl; bond (a) is a single or a double bond; b) R2 and R3 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; c) R4, R5 and R6 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino; halo; and 2-imidazolinylamino; and wherein one and only one of R4, R5 and R6 is 2-imidazolinylamino; d) R7 is selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; e) the compound is not 4-(2-imidazolinylamino)indole; enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, and pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for treating disorders modulated by alpha-2 adrenoceptors.